U.S. government expands assistance to J&J COVID-19 vaccine research

By The Science Advisory Board staff writers

November 16, 2020 -- The Biomedical Advanced Research and Development Authority (BARDA) is expanding its partnership with Johnson & Johnson by providing additional support for the ongoing development of its investigational COVID-19 vaccine candidate.

Under the amendment to the initial agreement, Janssen will commit approximately $604 million and BARDA will commit approximately $454 million to support the ongoing phase III Ensemble clinical trial evaluating the investigational COVID-19 vaccine candidate as a single-dose in up to 60,000 volunteers worldwide.

If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...
J&J pauses COVID-19 vaccine trials
Johnson & Johnson on October 12 temporarily paused further dosing in all of its COVID-19 vaccine clinical trials, including the phase III Ensemble...
J&J to supply EU with 200M COVID-19 vaccine doses
Johnson & Johnson has received approval from the European Commission to supply 200 million doses of Janssen Pharmaceutical's COVID-19 vaccine...
National Institutes of Health launches 4th phase III COVID-19 vaccine study
A phase III clinical trial evaluating the investigational Janssen COVID-19 vaccine Ad26.COV2.S for the prevention of symptomatic COVID-19 in a single-dose...
J&J to provide U.S. with 100M doses of COVID-19 vaccine
Johnson & Johnson will manufacture and deliver 100 million doses of its SARS-CoV-2 investigational vaccine to the U.S. government once it receives...

Copyright © 2020 scienceboard.net


Conferences
Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter